203 related articles for article (PubMed ID: 30294525)
1. Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan.
Hwang DK; Hwang YS; Tsai ML; Lin CJ; Chan WC; Chang YC; Chen DY; Hsieh TY; Sheu SJ; Lin CP
Taiwan J Ophthalmol; 2018; 8(3):117-120. PubMed ID: 30294525
[TBL] [Abstract][Full Text] [Related]
2. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
3. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor-α agents in noninfectious uveitis.
Gueudry J; LeHoang P; Bodaghi B
Dev Ophthalmol; 2012; 51():63-78. PubMed ID: 22517205
[TBL] [Abstract][Full Text] [Related]
5. Profile of adalimumab and its potential in the treatment of uveitis.
Balevic SJ; Rabinovich CE
Drug Des Devel Ther; 2016; 10():2997-3003. PubMed ID: 27698552
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
[TBL] [Abstract][Full Text] [Related]
7. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
[No Abstract] [Full Text] [Related]
8. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.
Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
Expert Opin Pharmacother; 2014 Oct; 15(15):2141-54. PubMed ID: 25226529
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab in the treatment of non-infectious uveitis.
Burek-Michalska A; Turno-Kręcicka A
Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for the treatment of uveitis.
LaMattina KC; Goldstein DA
Expert Rev Clin Immunol; 2017 Mar; 13(3):181-188. PubMed ID: 28140700
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
15. Indications and effects of biological agents in the treatment of noninfectious uveitis.
Li B; Yang L; Bai F; Tong B; Liu X
Immunotherapy; 2022 Aug; 14(12):985-994. PubMed ID: 35695019
[TBL] [Abstract][Full Text] [Related]
16. Biotherapies in Uveitis.
Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of adalimumab treatment for non-infectious uveitis.
Hasegawa E; Takeda A; Yawata N; Sonoda KH
Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
[TBL] [Abstract][Full Text] [Related]
18. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression for the Uveitides.
Jabs DA
Ophthalmology; 2018 Feb; 125(2):193-202. PubMed ID: 28942074
[TBL] [Abstract][Full Text] [Related]
20. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
Fan F; Zhou M; Luo Y
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
